drugset / Trial / NCT07077486
Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease
Phase 4
Recruiting
100 enrolled
Tongji Hospital
Johns Hopkins Bloomberg School of Public Health · collabRongchang Biopharmaceutical · collabWuhan Central Hospital · collabWuhan Hospital of Traditional Chinese Medicine · collab
Non-randomizedParallel-groupSingle-blindTreatment
Summary
Recent data indicate that Telitacicept is beneficial for lupus nephritis. Our goal is to determine whether Telitacicept is an effective and safe treatment, compared to standard-of-care Cyclophosphamide, for subclinical and clinical ILD in patients with early lupus.
Timeline
- Start
- 2025-08-25
- Primary completion
- 2026-10-25
- Completion
- 2027-03-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cyclophosphamide | Other / unclassified | 400 mg | Intravenous |
| Subject | Telitacicept | Protein / enzyme biologic | 80 mg | Subcutaneous |
| Subject | Telitacicept | Protein / enzyme biologic | 160 mg | Subcutaneous |
| Background | Methylprednisolone | Other / unclassified | 40 mg | — |